Research and Markets: Bispecific Antibodies: Clinical Trial Tracker Business Wire (press release) Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently ... |
